Aquestive Therapeutics offers a differentiated epinephrine product, Anaphylm, but faces pricing and market share headwinds. Learn why AQST stock is a hold.
Dividend-paying stocks, especially low-priced high-yield 'Dividend Dogs,' offer historically superior risk-adjusted returns and are undervalued relative to growth stocks. Read more here.
Target (TGT) jumps after HSBC upgrade to Buy and $190 price target, citing stronger traffic, comps, and margin upside--see what it means for investors now.
Vanguard Target Maturity 2031 Corporate Bond ETF (VBCE) - $0.2794. 30-Day SEC Yield of 5.43% as of Sept. 28. Payable Oct 05; for shareholders of record Oct 01;
Vanguard Target Maturity 2030 Corporate Bond ETF (VBCD) - $0.2606. 30-Day SEC Yield of 5.29% as of Sept. 28. Payable Oct 05; for shareholders of record Oct 01;
Vanguard Target Maturity 2029 Corporate Bond ETF (VBCC) - $0.2662. 30-Day SEC Yield of 5.16% as of Sept. 28. Payable Oct 05; for shareholders of record Oct 01;